A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes

NCT00324194 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia
Myelodysplastic Syndromes

Interventions

DRUG: MGCD0103

Sponsor

Mirati Therapeutics Inc.